Desmopressin
Also known as: DDAVP, Stimate, Minirin
Key Facts: Desmopressin
- Category
- Hormonal
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Multiple indications
- Administration
- Intranasal, oral, IV, or subcutaneous
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- FDA Approved
- Duration
- Varies by condition
What to Expect
A synthetic analog of vasopressin (ADH) used for diabetes insipidus, bedwetting, and bleeding disorders. Does not cause vasoconstriction like natural vasopressin.
Mechanism of Action
Desmopressin selectively activates V2 receptors in the kidneys, promoting water reabsorption without affecting V1 receptors (no blood pressure effects). Also releases von Willebrand factor and Factor VIII for hemostasis.
Research Summary
FDA approved since 1978 with extensive safety record. First-line treatment for central diabetes insipidus. Effective for nocturnal enuresis and certain bleeding disorders. Available in multiple formulations.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
FDA-approved dosing varies by indication
Doses from Studies
10-40 mcg intranasal
0.1-0.4 mg oral
0.3 mcg/kg IV for bleeding
Duration
Varies by condition
Administration
Intranasal, oral, IV, or subcutaneous
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Headache (common)
- ●HYPONATREMIA (major risk)
- ●Water intoxication (can cause seizures)
- ●Nausea
- ●Nasal congestion (spray)
- ●Thrombotic events (rare)
- ●FDA approved (DDAVP)
References
Related Peptides
Peptides commonly compared with Desmopressin or used in similar applications.
Oxytocin
FDAA naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.
HormonalGonadorelin
FDAA synthetic version of gonadotropin-releasing hormone. Used diagnostically and therapeutically for various reproductive and hormonal conditions.
HormonalLeuprolide
FDAA GnRH agonist that suppresses testosterone and estrogen production. FDA approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
HormonalOctreotide
FDAA synthetic somatostatin analog that inhibits multiple hormones. Used for acromegaly, carcinoid tumors, and various GI conditions.
HormonalLanreotide
FDAA long-acting somatostatin analog similar to octreotide. FDA approved for acromegaly and gastroenteropancreatic neuroendocrine tumors.
HormonalPasireotide
FDAA somatostatin analog with broader receptor binding than octreotide. Specifically effective for Cushing's disease due to SST5 activity.
HormonalWant updates on Desmopressin research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.